Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: 3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction

Figure 6

Possible mechanism for the synergistic combination of ECyd and CDDP through the dysfunction of Vaults. Vaults seem to be involved in the transport of biomolecules and drugs, and vRNAs, in particular, is thought to be an important component because of its interactions with anticancer drugs. vRNAs is transcribed by RNA polymerase III, which is a target of ECyd, and ECyd gives rise to immature and dysfunctional Vaults that does not contain vRNAs.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us